Galmed Acquires Colospan to Accelerate Product Launch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: Newsfilter
- Acquisition Restructuring: Galmed and Colospan agreed to restructure the acquisition terms, replacing the $2 million ordinary share issuance with an $800K cash payment and a risk-mitigated earnout of up to $2 million starting Q3 2027, aimed at minimizing dilution for existing shareholders.
- Product Launch Preparation: Galmed is laying the groundwork for a pan-European launch of CG-100, a device designed to protect colorectal anastomoses and reduce the need for diverting stomas, with revenue expected as early as 2026 and plans to submit data to the FDA to support its pivotal study.
- Clinical Data Support: CG-100 has treated 97 patients across four clinical trials, demonstrating a 90% avoidance rate of stoma creation, with a 0% device migration rate and safety data indicating 0% mortality, significantly outperforming traditional methods.
- Strategic Synergy: Galmed aims to establish a unified GI platform by integrating drug development with medical device commercialization, promoting the synergistic growth of CG-100 alongside its lead drug candidate Aramchol, thereby strengthening its market position in the GI sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLMD
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galmed Acquires Colospan to Accelerate Market Access
- Acquisition Restructuring: Galmed and Colospan restructured acquisition terms to mitigate dilution for existing shareholders, increasing cash payment by $800K while establishing a transparent, risk-mitigated earnout capped at $2 million, effective Q3 2027.
- Market Access for Products: Colospan's CG-100 product has received CE marking in the EU and OPS code for Germany, potentially allowing Galmed to generate revenue faster than traditional drug pipelines, enhancing its competitive edge in the market.
- Clinical Trial Results: To date, CG-100 has treated 97 patients across four clinical trials in Europe and Israel, with 90% avoiding stoma creation, demonstrating significant safety and efficacy advantages that further solidify Galmed's position in the gastrointestinal sector.
- Strategic Synergy: Galmed plans to leverage resources by integrating CG-100 with its Phase 3 ready lead drug candidate, Aramchol, aiming to reshape the standard of care for colorectal resection patients globally, thereby enhancing its status as a specialized GI medtech and biopharmaceutical platform.
See More
Galmed Acquires Colospan to Accelerate Product Launch
- Acquisition Restructuring: Galmed and Colospan agreed to restructure the acquisition terms, replacing the $2 million ordinary share issuance with an $800K cash payment and a risk-mitigated earnout of up to $2 million starting Q3 2027, aimed at minimizing dilution for existing shareholders.
- Product Launch Preparation: Galmed is laying the groundwork for a pan-European launch of CG-100, a device designed to protect colorectal anastomoses and reduce the need for diverting stomas, with revenue expected as early as 2026 and plans to submit data to the FDA to support its pivotal study.
- Clinical Data Support: CG-100 has treated 97 patients across four clinical trials, demonstrating a 90% avoidance rate of stoma creation, with a 0% device migration rate and safety data indicating 0% mortality, significantly outperforming traditional methods.
- Strategic Synergy: Galmed aims to establish a unified GI platform by integrating drug development with medical device commercialization, promoting the synergistic growth of CG-100 alongside its lead drug candidate Aramchol, thereby strengthening its market position in the GI sector.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Galmed Pharmaceuticals to Acquire Colospan in Strategic Move
- Acquisition Agreement: Galmed Pharmaceuticals has signed a definitive agreement to acquire Colospan, with the deal expected to close in Q2 2026, positioning Colospan as a wholly owned subsidiary and enhancing Galmed's market presence in colorectal surgery.
- Product Benefits: Colospan's lead product, the CG-100 intraluminal bypass device, is designed to reduce anastomotic leak complications and the need for diverting stomas after colorectal surgery, potentially improving patient recovery outcomes.
- Market Potential: The CG-100 is CE marked in Europe and currently undergoing a pivotal clinical trial in the U.S., which, if successful, could open new market opportunities for Galmed and strengthen its competitive product portfolio.
- Financial Terms: Under the deal, Colospan shareholders and SAFE holders will receive $2.5 million in cash and $2 million in Galmed shares at closing, reflecting Galmed's confidence in Colospan's future potential.
See More
Galmed Pharmaceuticals Acquires Colospan to Enhance GI Medtech Platform
- Acquisition Details: Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan for $2.5 million in cash and $2.0 million in ordinary shares, expected to close in Q2 2026, making Colospan a wholly owned subsidiary and advancing Galmed's diversified GI medtech strategy.
- Technological Integration Benefits: Colospan's CG-100 device, which has received FDA Breakthrough Device Designation, aims to reduce anastomotic leak risks in colorectal surgeries, and by leveraging Galmed's clinical expertise and resources, the acquisition is expected to accelerate the FDA application process, enhancing patient care standards.
- Market Demand Context: With approximately 1.9 million colorectal cancer cases diagnosed annually worldwide and anastomotic leaks occurring in up to 21% of procedures, leading to increased hospital stays and healthcare costs, Colospan's product addresses this clinical and economic burden, improving patient quality of life.
- Strategic Growth Outlook: This acquisition is viewed as a defining moment for Galmed, combining over 25 years of clinical execution capabilities, and is expected to expedite the CG-100 pivotal study, driving the company's growth and competitiveness in the global GI healthcare market.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified an unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing a new biological perspective for treating heart diseases that could potentially alter existing treatment strategies.
- Significant Drug Combination Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids, preserving cardiac muscle integrity and maintaining metabolic function, indicating its potential in cardiac fibrosis treatment.
- Clinical Development Prospects: Following the study results, Tissue Dynamics has filed a new patent and is preparing for future IND-enabling activities, highlighting the company's innovative capabilities and market potential in cardiac disease treatment.
- Strategic Collaboration Significance: The partnership between Galmed and Tissue Dynamics aims to leverage advanced AI technologies and human organoid models to advance research and development in cardiometabolic diseases, potentially providing more therapeutic options for fibrotic diseases and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Galmed Acquires Colospan to Accelerate Market Access
- Acquisition Restructuring: Galmed and Colospan restructured acquisition terms to mitigate dilution for existing shareholders, increasing cash payment by $800K while establishing a transparent, risk-mitigated earnout capped at $2 million, effective Q3 2027.
- Market Access for Products: Colospan's CG-100 product has received CE marking in the EU and OPS code for Germany, potentially allowing Galmed to generate revenue faster than traditional drug pipelines, enhancing its competitive edge in the market.
- Clinical Trial Results: To date, CG-100 has treated 97 patients across four clinical trials in Europe and Israel, with 90% avoiding stoma creation, demonstrating significant safety and efficacy advantages that further solidify Galmed's position in the gastrointestinal sector.
- Strategic Synergy: Galmed plans to leverage resources by integrating CG-100 with its Phase 3 ready lead drug candidate, Aramchol, aiming to reshape the standard of care for colorectal resection patients globally, thereby enhancing its status as a specialized GI medtech and biopharmaceutical platform.
See More
Galmed Acquires Colospan to Accelerate Product Launch
- Acquisition Restructuring: Galmed and Colospan agreed to restructure the acquisition terms, replacing the $2 million ordinary share issuance with an $800K cash payment and a risk-mitigated earnout of up to $2 million starting Q3 2027, aimed at minimizing dilution for existing shareholders.
- Product Launch Preparation: Galmed is laying the groundwork for a pan-European launch of CG-100, a device designed to protect colorectal anastomoses and reduce the need for diverting stomas, with revenue expected as early as 2026 and plans to submit data to the FDA to support its pivotal study.
- Clinical Data Support: CG-100 has treated 97 patients across four clinical trials, demonstrating a 90% avoidance rate of stoma creation, with a 0% device migration rate and safety data indicating 0% mortality, significantly outperforming traditional methods.
- Strategic Synergy: Galmed aims to establish a unified GI platform by integrating drug development with medical device commercialization, promoting the synergistic growth of CG-100 alongside its lead drug candidate Aramchol, thereby strengthening its market position in the GI sector.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Galmed Pharmaceuticals to Acquire Colospan in Strategic Move
- Acquisition Agreement: Galmed Pharmaceuticals has signed a definitive agreement to acquire Colospan, with the deal expected to close in Q2 2026, positioning Colospan as a wholly owned subsidiary and enhancing Galmed's market presence in colorectal surgery.
- Product Benefits: Colospan's lead product, the CG-100 intraluminal bypass device, is designed to reduce anastomotic leak complications and the need for diverting stomas after colorectal surgery, potentially improving patient recovery outcomes.
- Market Potential: The CG-100 is CE marked in Europe and currently undergoing a pivotal clinical trial in the U.S., which, if successful, could open new market opportunities for Galmed and strengthen its competitive product portfolio.
- Financial Terms: Under the deal, Colospan shareholders and SAFE holders will receive $2.5 million in cash and $2 million in Galmed shares at closing, reflecting Galmed's confidence in Colospan's future potential.
See More
Galmed Pharmaceuticals Acquires Colospan to Enhance GI Medtech Platform
- Acquisition Details: Galmed Pharmaceuticals announced a definitive agreement to acquire Colospan for $2.5 million in cash and $2.0 million in ordinary shares, expected to close in Q2 2026, making Colospan a wholly owned subsidiary and advancing Galmed's diversified GI medtech strategy.
- Technological Integration Benefits: Colospan's CG-100 device, which has received FDA Breakthrough Device Designation, aims to reduce anastomotic leak risks in colorectal surgeries, and by leveraging Galmed's clinical expertise and resources, the acquisition is expected to accelerate the FDA application process, enhancing patient care standards.
- Market Demand Context: With approximately 1.9 million colorectal cancer cases diagnosed annually worldwide and anastomotic leaks occurring in up to 21% of procedures, leading to increased hospital stays and healthcare costs, Colospan's product addresses this clinical and economic burden, improving patient quality of life.
- Strategic Growth Outlook: This acquisition is viewed as a defining moment for Galmed, combining over 25 years of clinical execution capabilities, and is expected to expedite the CG-100 pivotal study, driving the company's growth and competitiveness in the global GI healthcare market.
See More
Tissue Dynamics Uncovers New Mechanism of Cardiac Fibrosis
- New Mechanism Discovery: Tissue Dynamics identified an unrecognized metabolic mechanism driving cardiac fibrosis using human cardiac organoid models, providing a new biological perspective for treating heart diseases that could potentially alter existing treatment strategies.
- Significant Drug Combination Effects: The combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately fourfold (p<0.001) in inflammatory human cardiac organoids, preserving cardiac muscle integrity and maintaining metabolic function, indicating its potential in cardiac fibrosis treatment.
- Clinical Development Prospects: Following the study results, Tissue Dynamics has filed a new patent and is preparing for future IND-enabling activities, highlighting the company's innovative capabilities and market potential in cardiac disease treatment.
- Strategic Collaboration Significance: The partnership between Galmed and Tissue Dynamics aims to leverage advanced AI technologies and human organoid models to advance research and development in cardiometabolic diseases, potentially providing more therapeutic options for fibrotic diseases and enhancing the company's competitiveness in the biopharmaceutical sector.
See More
